Plain-English translation of NCT06121557 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Neoplasms research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase I trial testing a new type of treatment called lymph node-derived lymphocytes (LNLs) combined with and additional anti-cancer drugs. The treatment uses your body's own immune cells—collected from lymph nodes near your tumor—to help fight advanced HER2-negative breast cancer. Because this is early-stage research, the main goal is to make sure the treatment is safe.
Women with advanced HER2-negative breast cancer have few targeted treatment options, and current immunotherapy drugs don't work well enough for many patients. This medication and approach were designed to harness your immune system's own tumor-fighting cells, which may work better and avoid some of the problems seen with other cell-based treatments.
You likely qualify if…
You likely don't qualify if…
You would first have surgery to remove lymph nodes near your tumor so doctors can collect and grow your immune cells in the laboratory—this takes several weeks. Once ready, you would receive chemotherapy to prepare your body, followed by infusion of your own immune cells plus additional medication to boost their activity. After this, you would receive combined with another anti-cancer drug chosen by your doctor. The trial involves multiple visits to the hospital for infusions, blood tests, and scans to monitor how you're responding and check for side effects.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China